

Pharmacokinetic Parameters of Tibolone and Metabolites in Plasma, Urine, Feces, and Bile from Ovariectomized Cynomolgus Monkeys after a Single Dose or Multiple Doses of Tibolone. H. A. M. Verheul, C. J. Timmer, M. L. P. S. van Iersel, L. P. C. Delbressine, and H. J. Kloosterboer .......................... 1112

Application of the Dispersion Model to Describe Disposition Kinetics of Markers in the Dual Perfused Rat Liver. Selma Sahin and Malcolm Rowland .......................... 1119

Cytochrome P450 Eicosanoids are Activators of Peroxisome Proliferator-Activated Receptor α. Valerie Y. Ng, Yong Huang, L. Mannohman Reddy, John R. Falck, Emil T. Lin, and Deanna L. Kroetz .......................... 1126

Timolol Metabolism in Human Liver Microsomes Is Mediated Principally by CYP2D6. Marjo Volutinen, Miia Turpeinen, Ari Tolonen, Jouko Uusitalo, Jakka Mäenpää, and Olavi Pelkonen .......................... 1135

Improvement of the Oral Drug Absorption of Topotecan through the Inhibition of Intestinal Xenobiotic Efflux Transporter, Breast Cancer Resistance Protein, by Exciipients. Tetsuo Yamagata, Hiroyuki Kusuhara, Mariko Morishita, Kozo Takayama, Hassan Benameur, and Yuichi Sugiyama .......................... 1142

The Prokinetic Cinitapride Has No Clinically Relevant Pharmacokinetic Interaction and Effect on QT during Co-administration with Ketaconazole. Marta Robert, Miquel Salva, Rosa Segarra, Marco Pavesi, Ramón Esbri, David Roberts, and Georg Golor .......................... 1149


Abcg2/Bcrp1 Mediates the Polarized Transport of Antiretroviral Nucleosides Abacavir and Zidovudine. Guoyu Pan, Nagdeep Giri, and William F. Elmquist .......................... 1165

CYP2C9 Protein Interactions with Cytochrome b5: Effects on the Coupling of Catalysis. Charles W. Locuson, Larry C. Wienkers, Jeffrey P. Jones, and Timothy S. Tracy .......................... 1174

Predominant Contribution of UDP-Glucuronosyltransferase 2B7 in the Glucuronidation of Race- mic Furibiprofen in the Human Liver. Yuji Mano, Takashi Usui, and Hidetaka Kamimura .......................... 1182

Metabolism and Disposition of a Selective α2 Nicotinic Acetylcholine Receptor Agonist in Humans. Christopher L. Shaffer, Mithat Gunduz, Renato J. Scialis, and Annie F. Fang .......................... 1188


Esterase Inhibition by Grapefruit Juice Flavonoids Leading to a New Drug Interaction. Ping Li, Patrick S. Callery, Liang-Shang Gan, and Suresh K. Balani .......................... 1203

Impact of Genetic Knockout of PEPT2 on Cefadroxil Pharmacokinetics, Renal Tubular Reabsorption, and Brain Penetration in Mice. Hong Shen, Scott M. Ocheltree, Yongjun Hu, Richard F. Keep, and David E. Smith .......................... 1209

Selective Toxicity of Aristolochic Acids I and II. Shinya Shibutani, Huan Dong, Naomi Suzuki, Shiro Ueda, Frederick Miller, and Arthur P. Grollman .......................... 1217


Isolation and Characterization of Polyspecific Mouse Organic Solute Carrier Protein 1 (mOscp1). Yasuna Kobayashi, Ayumi Tsu-chiya, Tomofumi Hayashi, Noriko Kohyama, Masayuki Ohbayashi, and Toshinori Yamamoto. 1239

ERRATUM
Correction to “Three-Dimensional Quantitative Structure-Activity Relationship Analysis of Human CYP51 Inhibitors”. S. Ekins, D. C. Mankowski, D. J. Hoover, M. P. Lawton, J. L. Treadway, and H. J. Harwood, Jr. 1246

Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: A diagram showing the relationship between % remaining and the therapeutic blood or plasma concentration of 171 marketed compounds in which in vivo DDI information was incorporated. See the article by Watanabe et al. in this issue on page 1232.